GNLKQ (Genelink) ROCE %: 0.00% (As of Sep. 2013)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genelink ROCE %?

Genelink GNLKQ ROCE % is 0.00% as of Sep. 2013.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genelink's annualized ROCE % for the quarter that ended in Sep. 2013 was 0.00%.

Genelink  (OTCPK:GNLKQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genelink ROCE % Related Terms

Genelink ROCE % Historical Data

* Premium members only.

The historical data trend for Genelink's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genelink ROCE % Chart

Genelink Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -693.73 -2,512.62 -2,233.49 -1,307.89 -5,442.00

Genelink Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genelink ROCE % Calculation

Genelink's annualized ROCE % for the fiscal year that ended in Dec. 2012 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2012 )  (A: Dec. 2011 )(A: Dec. 2012 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2012 )  (A: Dec. 2011 )(A: Dec. 2012 )
=-2.721/( ( (2.78 - 2.296) + (1.455 - 1.839) )/ 2 )
=-2.721/( (0.484+-0.384)/ 2 )
=-2.721/0.05
=-5,442.00 %

Genelink's ROCE % of for the quarter that ended in Sep. 2013 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2013 )  (Q: Jun. 2013 )(Q: Sep. 2013 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2013 )  (Q: Jun. 2013 )(Q: Sep. 2013 )
=-2.412/( ( (1.273 - 2.114) + (1.284 - 2.243) )/ 2 )
=-2.412/( ( -0.841 + -0.959 )/ 2 )
=-2.412/-0.9
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2013) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Genelink (GNLKQ) has a ROCE % of 0.00% as of Sep. 2013.
Is Genelink's ROCE % too high?
Genelink's current ROCE % is 0.00%.
How does Genelink's ROCE % compare to VITIF and HSTC?
Genelink's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Genelink's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genelink stock overvalued right now?
Genelink (GNLKQ) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Genelink (GNLKQ), the current ROCE % is 0.00% as of Sep. 2013. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genelink Business Description

Address 8250 Exchange Drive, Suite 120, Orlando, FL, USA, 32809
Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.